Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00459381
Other study ID # NCI-2012-02710
Secondary ID NABTC-0602U01CA0
Status Completed
Phase Phase 2
First received April 9, 2007
Last updated February 1, 2013
Start date May 2007

Study information

Verified date January 2013
Source National Cancer Institute (NCI)
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This phase II trial is studying the side effects and how well pazopanib works in treating patients with recurrent glioblastoma. Pazopanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor


Description:

PRIMARY OBJECTIVES:

I. Determine the therapeutic efficacy of pazopanib hydrochloride, as measured by 6-month progression-free survival (PFS), in patients with recurrent glioblastoma.

II. Determine the safety profile of this drug in these patients.

SECONDARY OBJECTIVES:

I. Determine the efficacy of this drug, as measured by radiographic response, time to progression, and overall survival, in these patients.

OUTLINE: This is a multicenter study.

Patients receive oral pazopanib hydrochloride daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed periodically for at least 2 years.


Recruitment information / eligibility

Status Completed
Enrollment 35
Est. completion date
Est. primary completion date December 2008
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Histologically confirmed glioblastoma multiforme, including gliosarcoma

- Recurrent disease

- Must have unequivocal radiographic evidence of tumor progression by MRI, as defined by any of the following:

- 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline

- Clear worsening of any evaluable disease

- Appearance of any new lesions or site

- Clear clinical worsening

- Must have failed prior radiotherapy that was completed = 42 days ago

- Patients who received prior therapy that included interstitial brachytherapy or stereotactic radiosurgery must have confirmation of true progressive disease, rather than radiation necrosis, based on positron emission tomography (PET) scan, thallium scanning, magnetic resonance spectroscopy, or surgical documentation of disease

- Treatment for no more than 2 prior relapses allowed

- Relapse is defined as progression following initial therapy (i.e., radiotherapy with or without chemotherapy, if that was used as initial therapy; therefore no more than 3 prior therapies [initial therapy and therapy for 2 relapses] allowed)

- If the patient had a surgical resection for relapsed disease and no anticancer therapy was instituted for up to 12 weeks, and the patient undergoes another surgical resection, this is considered as 1 relapse

- For patients who had prior therapy for a low-grade glioma, the surgical diagnosis of a glioblastoma multiforme will be considered the first relapse

- Karnofsky performance status 60-100%

- Life expectancy > 8 weeks

- WBC = 3,000/mm^3

- Absolute neutrophil count = 1,500/mm^3

- Hemoglobin = 10 g/dL (may be reached by transfusion)

- Platelet count = 100,000/mm^3

- PT/INR/PTT = 1.2 times upper limit of normal (ULN)

- SGOT < 2.5 times ULN

- Bilirubin < 2.5 times ULN

- Creatinine < 1.5 mg/dL OR creatinine clearance = 60 mL/min

- Urine protein:creatinine ratio > 1 OR urine protein < 1,000 mg by 24-hour urine collection OR proteinuria < 1+

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective double-barrier contraception during study therapy OR practice abstinence from sexual intercourse for 14 days prior to, during, and for = 21 days after study therapy

- Systolic blood pressure (BP) = 140 mm Hg and diastolic BP = 90 mm Hg

- Prior initiation or adjustment of BP medication allowed provided the average of 3 BP readings is = 140/90 mm Hg

- No uncontrolled significant medical illnesses that would preclude study therapy

- No other conditions, including any of the following:

- Serious or nonhealing wound, ulcer, or bone fracture

- Abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 28 days

- Cerebrovascular accident (CVA) within the past 6 months

- Myocardial infarction, cardiac arrhythmia, admission for unstable angina, cardiac angioplasty, or stenting within the past 84 days

- Venous thrombosis within the past 84 days

- New York Heart Association (NYHA) class III or IV heart failure

- Asymptomatic NYHA class II heart failure while on treatment allowed

- No other cancer except for nonmelanoma skin cancer or carcinoma in situ of the cervix unless in complete remission and off of all therapy for that disease for = 3 years

- No disease that would obscure toxicity or dangerously alter drug metabolism

- No history of allergic reactions attributed to compounds of similar chemical or biological composition to pazopanib hydrochloride or other agents

- No QTc prolongation (i.e., QTc interval = 500 msecs) or other significant ECG abnormalities

- No condition that impairs the ability to swallow and retain pazopanib hydrochloride, including any of the following:

- Gastrointestinal tract disease resulting in an inability to take oral medication

- Requirement for IV alimentation

- Prior surgical procedures affecting absorption

- Active peptic ulcer disease

- See Disease Characteristics

- Recovered from prior therapy

- At least 28 days since prior resection of recurrent or progressive tumor and recovered

- Residual disease after resection of recurrent glioblastoma is not mandated for eligibility into the study

- More than 7 days since prior noncytotoxic agents (e.g., interferon, tamoxifen, thalidomide, or isotretinoin)

- Radiosensitizers allowed

- More than 14 days since prior investigational agents

- More than 14 days since prior vincristine

- More than 21 days since prior procarbazine

- More than 28 days since prior cytotoxic therapy

- More than 42 days since prior nitrosoureas

- No prior bevacizumab

- No prior sorafenib tosylate or sunitinib malate

- No prior pazopanib hydrochloride

- No concurrent CYP2C9 substrates, including any of the following:

- Anticoagulants (e.g., warfarin [therapeutic doses only])

- Oral hypoglycemics (e.g., glipizide, glyburide, tolbutamide, glimepiride, or nateglinide)

- Ergot derivatives (e.g., dihydroergotamine, ergonovine, ergotamine, or methylergonovine)

- Neuroleptics (e.g., pimozide)

- Erectile dysfunction agents (e.g., sildenafil, tadalafil, or vardenafil)

- Antiarrhythmics (e.g., bepridil, flecainide, lidocaine, mexilitine, amiodarone, quinidine, or propafenone)

- Immune modulators (e.g., cyclosporine, tacrolimus, or sirolimus)

- Miscellaneous drugs (e.g., theophylline, quetiapine, risperidone, tacrine, clozapine, or atomoxetine)

- No concurrent combination antiretroviral therapy for HIV-positive patients

- No other concurrent anticancer therapy (including chemotherapy, radiotherapy, hormonal treatment, or immunotherapy) or investigational drugs

- No concurrent enzyme-inducing anti-epileptic drugs (EIAEDs)

- Non-EIAEDs allowed

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
pazopanib hydrochloride
Given orally
Other:
laboratory biomarker analysis
Correlative studies

Locations

Country Name City State
United States North American Brain Tumor Consortium Watertown Massachusetts

Sponsors (1)

Lead Sponsor Collaborator
National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Progression-free survival 6 months No
Secondary Toxicity evaluated according to the NCI Common Toxicity Criteria (CTCAE) version 3.0 Up to 2 years Yes
Secondary Time to treatment failure From date of registration to the date of first observation of progressive disease, non-reversible neurologic progression or permanently increased steroid requirement, death due to any cause, or early discontinuation of treatment, assessed up to 2 years No
Secondary Overall survival From date of registration to date of death due to any cause, assessed up to 2 years No
See also
  Status Clinical Trial Phase
Terminated NCT02530502 - Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly Diagnosed Glioblastoma Phase 1
Withdrawn NCT02194452 - Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors N/A
Completed NCT00238303 - Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme Phase 2
Completed NCT02227901 - Tipifarnib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Phase 1
Completed NCT00049387 - Tipifarnib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma Phase 1
Completed NCT02015819 - Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas Phase 1
Active, not recruiting NCT02179086 - Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Phase 2
Recruiting NCT04573140 - A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM) Phase 1
Active, not recruiting NCT00823797 - Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma Phase 2
Completed NCT00045565 - Arsenic Trioxide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma Phase 1
Completed NCT01977677 - Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma Phase 1/Phase 2
Completed NCT01648348 - Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme Phase 1/Phase 2
Completed NCT00004262 - Radiation Therapy and Gadolinium Texaphyrin in Treating Patients With Supratentorial Glioblastoma Multiforme Phase 1
Terminated NCT01996527 - 3T MRI Biomarkers of Glioma Treatment Response Early Phase 1
Terminated NCT01575275 - Aminolevulinic Acid in Visualizing a Tumor During Surgery in Patients With Glioblastoma Multiforme Phase 2
Completed NCT01131234 - Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors Phase 1
Terminated NCT01103375 - Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant Glioma Phase 1
Completed NCT01119599 - RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma Phase 1
Completed NCT00316849 - Temsirolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Phase 1
Completed NCT00016328 - CCI-779 in Treating Patients With Recurrent Glioblastoma Multiforme Phase 2